{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:29:22Z","timestamp":1771036162361,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The substitution of generic drugs can effectively alleviate the rapid growth of drug costs; however, the clinical effectiveness and medical costs of originator products and generics were barely studied in China.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> To compare the effectiveness of antihypertensive drugs and hypertension-related medical costs between originator and generic initiators in Yinzhou, China.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a population-based retrospective cohort study using the Chinese Electronic Health Records Research in Yinzhou (CHERRY), from July 1, 2011, to December 31, 2018. Hypertension patients initiating with originator products were compared with patients initiating with generic counterparts. We used 1:1 propensity score matching to pair the two groups based on sociodemographic, clinical, and health service utilization variables. Cox proportional regression was adopted to compare the rate of hospitalization for hypertension-related cardiovascular disease between matched originator and generic initiators. Wilcoxon matched-pairs signed-rank test was used to compare annual hypertension-related medical costs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Matched pairs (10,535) of patients were included in the comparative study of originator products and generics, corresponding to seven antihypertensive drugs including amlodipine, felodipine, nifedipine, irbesartan, losartan, valsartan, and metoprolol. The average age of patients included in the analysis was around 60\u00a0years (originator <jats:italic>vs<\/jats:italic>. generics initiators: from 59.0 <jats:italic>vs<\/jats:italic>. 59.1\u00a0years in losartan to 62.9 <jats:italic>vs<\/jats:italic>. 63.6\u00a0years in nifedipine). Higher hospitalization rates among originator initiators were observed for three calcium channel blockers (hazard ratio[95% CI]: amlodipine, 3.18[1.43, 7.11]; felodipine, 3.60[1.63, 7.98]; and nifedipine, 3.86[1.26, 11.81]; respectively). The remaining four out of seven drugs of the clinical endpoint estimates showed comparable outcomes between originator products and generics (hazard ratio[95% CI]: irbesartan, 1.19[0.50, 2.84]; losartan, 1.84[0.84, 4.07]; valsartan, 2.04[0.72, 5.78]; and metoprolol, 1.25[0.56, 2.80]; respectively). Higher median annual hypertension-related medical costs were observed in originator initiators (all <jats:italic>p<\/jats:italic>\u00a0&amp;lt;\u00a00.001), except for metoprolol (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.646).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We observed comparable or even better clinical outcomes and less medical cost associated with the use of antihypertensive generics compared to originator counterparts. This could help increase patient and provider confidence in the efficacy of generic medicines to manage hypertension diseases.<\/jats:p>","DOI":"10.3389\/fphar.2022.757398","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:29:44Z","timestamp":1645511384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China"],"prefix":"10.3389","volume":"13","author":[{"given":"Tao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haishaerjiang","family":"Wushouer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luwen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal Caliper Widths for Propensity-Score Matching when Estimating Differences in Means and Differences in Proportions in Observational Studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm. Stat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The Performance of Different Propensity Score Methods for Estimating Marginal hazard Ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.sapharm.2010.06.004","article-title":"Evaluating Pharmacists' Views, Knowledge, and Perception Regarding Generic Medicines in New Zealand","volume":"7","author":"Babar","year":"2011","journal-title":"Res. Soc. Adm Pharm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e000438","DOI":"10.1136\/openhrt-2016-000438","article-title":"Health System Barriers and Facilitators to Medication Adherence for the Secondary Prevention of Cardiovascular Disease: a Systematic Review","volume":"3","author":"Banerjee","year":"2016","journal-title":"Open Heart"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1097\/HJH.0000000000000130","article-title":"Medication Persistence and the Use of Generic and Brand-Name Blood Pressure-Lowering Agents","volume":"32","author":"Corrao","year":"2014","journal-title":"J. Hypertens."},{"key":"B6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/HJH.0b013e3282f4edd7","article-title":"Discontinuation of and Changes in Drug Therapy for Hypertension Among Newly-Treated Patients: a Population-Based Study in Italy","volume":"26","author":"Corrao","year":"2008","journal-title":"J. Hypertens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1002763","DOI":"10.1371\/journal.pmed.1002763","article-title":"Comparative Effectiveness of Generic and Brand-Name Medication Use: A Database Study of US Health Insurance Claims","volume":"16","author":"Desai","year":"2019","journal-title":"Plos Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12916-015-0415-3","article-title":"What Do People Really Think of Generic Medicines? A Systematic Review and Critical Appraisal of Literature on Stakeholder Perceptions of Generic Drugs","volume":"13","author":"Dunne","year":"2015","journal-title":"BMC Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/11585970-000000000-00000","article-title":"Does the Market Share of Generic Medicines Influence the price Level?: a European Analysis","volume":"29","author":"Dylst","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.7326\/M13-2942","article-title":"Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: a Cohort Study","volume":"161","author":"Gagne","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yebeh.2015.08.014","article-title":"Comparative Effectiveness of Generic versus Brand-Name Antiepileptic Medications","volume":"52","author":"Gagne","year":"2015","journal-title":"Epilepsy Behav."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2217\/cer-2020-0273","article-title":"Evidence-based Public Policy Making for Medicines across Countries: Findings and Implications for the Future","volume":"10","author":"Godman","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fphar.2014.00106","article-title":"Multiple Policies to Enhance Prescribing Efficiency for Established Medicines in Europe with a Particular Focus on Demand-Side Measures: Findings and Future Implications","volume":"5","author":"Godman","year":"2014","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.7326\/0003-4819-142-11-200506070-00006","article-title":"Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000","volume":"142","author":"Haas","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication Adherence: its Importance in Cardiovascular Outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00318","DOI":"10.1002\/prp2.318","article-title":"Make up a Missed Lesson-New Policy to Ensure the Interchangeability of Generic Drugs in China","volume":"5","author":"Huang","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e015302","DOI":"10.1161\/JAHA.119.015302","article-title":"Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability","volume":"9","author":"Husain","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5246\/jcps.2020.05.034","article-title":"Pharmacists' Perceptions of Generic Drugs in China","volume":"29","author":"Jiang","year":"2020","journal-title":"J. Chin. Pharm. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1001\/jama.2008.758","article-title":"Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: a Systematic Review and Meta-Analysis","volume":"300","author":"Kesselheim","year":"2008","journal-title":"Jama"},{"key":"B20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-020-01296-x","article-title":"Are Generic Drugs Used in Cardiology as Effective and Safe as Their Brand-Name Counterparts? A Systematic Review and Meta-Analysis","volume":"80","author":"Leclerc","year":"2020","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamainternmed.2016.0190","article-title":"The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China","volume":"176","author":"Lewington","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The Robust Inference for the Cox Proportional Hazards Model","volume":"84","author":"Lin","year":"1989","journal-title":"J. Am. Stat. Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e019698","DOI":"10.1136\/bmjopen-2017-019698","article-title":"Using Big Data to Improve Cardiovascular Care and Outcomes in China: a Protocol for the Chinese Electronic Health Records Research in Yinzhou (CHERRY) Study","volume":"8","author":"Lin","year":"2018","journal-title":"BMJ Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","article-title":"Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from 1\u00b77 Million Adults in a Population-Based Screening Study (China PEACE Million Persons Project)","volume":"390","author":"Lu","year":"2017","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr. Epidemiol. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e89168","DOI":"10.1371\/journal.pone.0089168","article-title":"Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: a Systematic Review","volume":"9","author":"Mann","year":"2014","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","article-title":"Generic versus Brand-Name Drugs Used in Cardiovascular Diseases","volume":"31","author":"Manzoli","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.sapharm.2019.08.031","article-title":"Impact of U.S. Federal and State Generic Drug Policies on Drug Use, Spending, and Patient Outcomes: A Systematic Review","volume":"16","author":"Mishuk","year":"2020","journal-title":"Res. Soc. Adm Pharm"},{"key":"B29","unstructured":"Data Query: National Medical Products Administration2020"},{"key":"B30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.yebeh.2012.10.032","article-title":"Generic Substitution in the Treatment of Epilepsy: Patient Attitudes and Perceptions","volume":"26","author":"Ngo","year":"2013","journal-title":"Epilepsy Behav."},{"key":"B31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s0895-4356(00)00321-8","article-title":"Validating Recommendations for Coronary Angiography Following Acute Myocardial Infarction in the Elderly: a Matched Analysis Using Propensity Scores","volume":"54","author":"Normand","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1377\/hlthaff.2009.0424","article-title":"State Generic Substitution Laws Can Lower Drug Outlays under Medicaid","volume":"29","author":"Shrank","year":"2010","journal-title":"Health Aff. (Millwood)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/archinte.166.3.332","article-title":"The Implications of Choice: Prescribing Generic or Preferred Pharmaceuticals Improves Medication Adherence for Chronic Conditions","volume":"166","author":"Shrank","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10557-013-6497-2","article-title":"Patient Co-payment and Adherence to Statins: a Review and Case Studies","volume":"28","author":"Simoens","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e64914","DOI":"10.1371\/journal.pone.0064914","article-title":"The Effect of Copayments for Prescriptions on Adherence to Prescription Medicines in Publicly Insured Populations; a Systematic Review and Meta-Analysis","volume":"8","author":"Sinnott","year":"2013","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/S0140-6736(17)32476-5","article-title":"Availability, Cost, and Prescription Patterns of Antihypertensive Medications in Primary Health Care in China: a Nationwide Cross-Sectional Survey","volume":"390","author":"Su","year":"2017","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1097\/MLR.0b013e3181484347","article-title":"Cross-national Comparative Performance of Three Versions of the ICD-10 Charlson index","volume":"45","author":"Sundararajan","year":"2007","journal-title":"Med. Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1007\/s40258-014-0145-2","article-title":"A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What Are the Global Challenges?","author":"Toverud","year":"2015","journal-title":"Appl. Health Econ. Health Pol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10198-011-0367-2","article-title":"Patient Socioeconomic Determinants for the Choice of the Cheapest Molecule within a Cluster: Evidence from Belgian Prescription Data","volume":"13","author":"Vrijens","year":"2012","journal-title":"Eur. J. Health Econ."},{"key":"B40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jch.13803","article-title":"What Is New in the 2018 Chinese Hypertension Guideline and the Implication for the Management of Hypertension in Asia?","volume":"22","author":"Wang","year":"2020","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B41","volume-title":"Cost Savings of Switching Private Sector Consumption from Originator Brands to Generic Equivalents","year":"2010"},{"key":"B42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40264-017-0589-z","article-title":"Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China","volume":"41","author":"Yang","year":"2018","journal-title":"Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/1472-6963-13-390","article-title":"A price and Use Comparison of Generic versus Originator Cardiovascular Medicines: a Hospital Study in Chongqing, China","volume":"13","author":"Zeng","year":"2013","journal-title":"BMC Health Serv. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.3390\/ijerph16224578","article-title":"Trends and Inequalities in the Health Care and Hypertension Outcomes in China, 2011 to 2015","volume":"16","author":"Zhao","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.757398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:29:48Z","timestamp":1645511388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.757398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":44,"alternative-id":["10.3389\/fphar.2022.757398"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.757398","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"article-number":"757398"}}